Cell Culture Engineering XIV

Poster List
(March 31, 2014)

1. **Systematic evaluation of commonly-used and uncommonly-used cell culture media compounds for the targeted shifting of protein glycosylation profiles of recombinant antibodies and dual-variable domain immunoglobulins**
   Patrick M. Hossler, AbbVie Biotherapeutics Inc.

2. **From DNA to 1 kg in 80 days**
   Taymar E. Hartman, AbbVie Biotherapeutics Inc.

3. **Challenges to produce effective mixing for powder media formulations used for CHO cell growth and mab production**
   Michael Hippach, Agensys, Inc

4. **Metabolomic profiling as a tool for feed development**
   Anne Kantardjieff, Alexion Pharmaceuticals

5. **Deciphering factors that have impacts on glycosylation of mAb and its biophysical properties**
   Zhimei Du, Amgen

6. **Increasing high mannose glycan species of recombinant proteins through glucose limitation and alternative carbon sources**
   Jian Wu, Amgen

7. **Uncovering methods for the prevention of protein aggregation and improvement of product quality in a transient expression system**
   Bram Estes, Amgen

8. **Improved quality and productivity in pseudo-perfusion cultures of self-degradation protein**
   Masami Yokota, Astellas Pharma Inc.

9. **Challenges and lessons learned during scale up and tech transfer of a non-platform NS0 process**
   Mei Shao, AstraZeneca

10. **Quantification of genomic rearrangements in CHO cell lines by AFLP**
    Inmaculada Hernandez Lopez, Austrian Center of Industrial Biotechnology

11. **Implementation of a small scale, medium throughput microRNA screening assay based on mimics for Chinese hamster ovary cells**
    Gerald Klanert, Austrian Center of Industrial Biotechnology

12. **Addressing changes to critical raw materials**
    Yuval Shimoni, Bayer

13. **Gaining optimized cell-level observability and data-driven process guidance by leveraging on-line technologies such as dielectric spectroscopy and at-line tools such as the modular automated sampling technology (MAST-TM) platform**
    Clinton B. Pepper, Bend Research, Inc.
14. Interpretation and prediction of cell culture performance utilizing a combination of metabolic flux analysis and statistical methods
   Amber Broadbent, Bend Research, Inc.

15. Using dielectric spectroscopy to non-invasively measure cell physiological properties in a bioreactor
   Brandon, J. Downey, Bend Research, Inc.

16. Exploring the promoter landscape of the Chinese hamster by next-generation RNA sequencing
   Thomas Noll, Bielefeld University

17. Secretion augmentation via host cell engineering to improve CHO cell productivity
   Scott D. Estes, Biogen Idec, Inc.

18. Ambr as a qualified scale down model for process development and process characterization
   Yao-Ming Huang, Biogen Idec, Inc.

19. Integrated cell line and process development for a difficult to express protein
   Alan Gilbert, Biogen Idec, Inc.

20. Evolution in our understanding of raw materials variability and management of the impact on upstream processes throughout commercial product lifecycle
   Hang Yuan, Biogen Idec, Inc.

21. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality
   William C. Yang, Biogen Idec, Inc.

22. Simultaneous measurement of CO2 and O2 mass transfer coefficients for modeling of dissolved carbon dioxide and oxygen across bioreactor scales
   Vijay Janakiraman, Biogen Idec, Inc.

23. CHippO: Manipulation of the Hippo signaling pathway in CHO to produce a superior host for recombinant protein expression
   John Follit, Biogen Idec, Inc.

24. Reactive oxygenated species can initiate apoptosis in CHO cells, disrupt the lysosome membrane and trigger the release of cathepsin d into the cytosol
   Sumitra Nadarajah, BioMarin Pharmaceutical

25. Investigating the impact of sparger design on fouling to address sialic acid content variability in large scale perfusion cultures
   Benjamin Youn, BMRN

26. Characterization of production bioreactors and media preparation tanks for process development and manufacturing
   Chung Chun, Boehringer Ingelheim

27. High-throughput process development strategy for biologics DS manufacturing
   Jongchan Lee, Bristol-Myers Squibb

28. Developing cell lines for industrial processes: An integrated methodology
   Adolfo Jose Castillo-Vitlloch, Center of Molecular Immunology
29. **Expression of difficult to express proteins in the human CAP cell line**  
   Jens Wolff, Cevec Pharmaceuticals GmbH

30. **A long non-coding RNA, which is abnormally overexpressed in high titer cells, can improve mAB yield and have efficacy in transgene co-overexpression**  
   Hisahiro Tabuchi, Chugai Pharmaceutical Co., Ltd.

31. **Bioreactor control algorithms and process developments for improved stem cell expansion**  
   Sarah W. Harcum, Clemson University

32. **Dielectric spectroscopy as real-time monitoring tool for critical phases of cell viral production.**  
   Emma Petiot, CPE-Lyon Engineer School

33. **Detection and quantification of the misspliced form transcribed from an antibody heavy chain gene and inhibition of missplicing by changing the codon of a single amino acid**  
   Kenji Masuda, Daiichi Sankyo Co., LTD

34. **Mining CHO cell OMICS’ data: Beyond differential expression analysis**  
   Colin Clarke, Dublin City University

35. **Fed-batch cultivation of PYC2-expressing cells: An integrated cellular and process engineering approach to enhance cell culture performance**  
   Olivier Henry, Ecole Polytechnique de Montreal

36. **Production and purification of biotin-tagged ectodomains of FcγRs, by co-transfection of BirA enzyme plasmid in mammalian cells**  
   July Dorion-Thibaudeau, Ecole Polytechnique de Montreal

37. **Plasmid-based rapid recombinant protein production in insect cells**  
   Xiao Shen, Ecole Polytechnique Federale de Lausanne

38. **The effects of supplement and cell culture process on monoclonal antibody and recombinant protein productivity improvement**  
   Hui-Chun Li, EirGenix

39. **Control of galactosylated glycoforms distribution in cell culture system**  
   Anli Ouyang, Eli Lilly

40. **Biosimilar development: A tale of two models**  
   Mark Melville, Epirus Biopharmaceuticals

41. **Evaluation of culture conditions and productivity enhancers in a CHO cell-based perfusion process**  
   Juliana Coronel, Federal University of Rio de Janeiro

42. **Polyisoprenylated methylated protein methyl esterase activity is vital for cell proliferation and survival**  
   Felix Amissah, Florida A&M University

43. **RMCE-based cell line development: towards predictable and reproducible transgene expression?**  
   Elisabeth Bludau, Fraunhofer ITEM
44. Optimization and control of monoclonal antibody product quality using a media and process toolbox approach
   Min Zhang, Fujifilm Diosynth Biotechnologies

45. Using a directed evolution approach to identify CHO host cell lines with improved characteristics
   Fay Saunders, Fujifilm Diosynth Biotechnologies

46. A streamlined single-use solution for intensified high-density cell culture processes
   Zhou Jiang, GE Healthcare

47. Red-colored IgG4 caused by vitamin B12 from cell culture media combined with disulfide reduction at harvest
   Gayle E. Derfus, Gilead

48. Improvement of recombinant protein production in insect cells: New host endogenous Sf21 promoters and fast generation of tailored cell lines
   Maren Bleckmann, Helmholtz Center

49. Insights into the metabolism of CHO cells under key nutrient limitations
   Tiago Martin, IBET/ITQB-UNL

50. Model-based optimization toward cell death suppression in a fed-batch culture of GS-NS0 cell line for production of monoclonal antibody
   Chonlatep Usaku, Imperial College London

51. Live-cell imaging of baculovirus-infected insect cells
   David Hidalgo, Instituto de Biotecnologia, UNAM

52. Development of an expression platform for alternative scaffold therapeutics
   Kevin D. Smith, Janssen

53. High throughput RNA interference for improved functional expression of neurotensin receptor
   Su Xiao, Johns Hopkins University/ National Institutes of Health

54. Effect of glutamine substitution by TCA cycle intermediates on the production and sialylation of Fc-fusion protein in Chinese hamster ovary cell culture
   Tae Kwang Ha, KAIST

55. Impact of metabolic characteristics of a cell line on process scale-up
   Sigma Mostafa, KBI Biopharma Inc.

56. A method to optimize the cell specific perfusion rate in perfusion process
   Ye Zhang, KTH - Royal Institute of Technology

57. Extreme cell densities of CHO cells in perfused stirred tank bioreactor
   Veronique Chotteau, KTH - Royal Institute of Technology

58. Condensed inoculating process aiming enhancing productivity and simplifying operation
   Yasufumi Imamoto, Kyowa Hakko kirin Co., Ltd.

59. Identification of a novel antiviral protein from Phyllocaulis boraceiensis mucus, and activity analysis by real time PCR
   Ronaldo Mendonca, Laboratorio de Parasitologia Instituto Butantan
60. Influence of osmolality in culture medium on galactosylation
    Jun Jung, LG Life Sciences

61. Enhanced effector function of human T lymphocytes grown ex vivo in serum-free medium
    Angel Varela-Rohena angel, Life Technologies, Inc

62. A commonly used signal peptide has a major impact on protein expression in mammalian cells
    Paula Ravnikar, Life Technologies, Inc

63. Improved manufacturability of fed-batch systems employing highly concentrated feeds
    Shawn Barrett, Life Technologies, Inc

64. Use of high-throughput media design and novel components to increase monoclonal antibody titer and maintain product quality
    Michael Gillmeister, Life Technologies, Inc

65. Assessment of hybrid CMV promoters in site-specific integration and random integration CHO cell lines
    Tom Payne, Lonza Biologics

66. Utilizing Chinese hamster ovary cell population heterogeneity for the isolation of new host cell lines with enhanced performance
    Peter M. O'Callaghan, Lonza Biologics

67. Bioproduction using large-scale transient transfection: From >1 gram/l antibody titers via transient gene expression to rapid, high-yield stable cell line generation
    Weili Wang, MaxCyte

68. Case study: Implementation of a novel cell line development strategy using a single round of facs cloning to accelerate project timelines
    Eileen M. Higham, Medimmune

69. Use of ITRAQ and free-labeling proteomics to study CHO antibody expressing cell lines
    Deniz Baycin Hizal, MedImmune

70. High throughput cell culture media component screening
    Kelley M. Heffner, MedImmune

71. Gas transfer characterization methodology to improve bioreactor scale-down performance
    Michael Mollet, MedImmune

72. The importance of media selection and scale-down models for high-titer expression in CHO cells
    Sebastien Ribault, Merck

73. Development of a novel tetravalent recombinant vaccine to prevent C.difficile associated disease
    Shyamsundar Subramania, Merck

74. The integration of upstream process development, technology transfer, and clinical manufacture enabled by Multivariate Data Analysis (MVDA)
    Hao Chen, Merck
75. On-line dielectric spectroscopy for optimal harvest timing of a lytic virus produced on microcarriers
   David Pajerowski, Merck and Company

76. Modulation of monoclonal antibody quality attributes using micro-l scale fed-batch cultures
   Matthieu Stettler, Merck Serono

77. Monte Carlo simulations: A practical tool for setting process proven acceptable ranges for a Mab producing cell culture process.
   Ronald Eimers, Merck Sharp & Dohme

78. Comparison of expression systems for stable cell line and pool generation
   Benjamin Wang, Merrimack Pharmaceuticals

79. Production of sialylated antibodies in CHO cells
   Celine Raymond, National Research Council of Canada

80. Development of high cell density fed-batch culture process to improve productivity of influenza virus for vaccine manufacturing
   Chun Fang Shen, National Research Council of Canada

81. Different immunity elicited by recombinant H5N1 hemagglutinin glycoproteins containing pauci-mannose, high-mannose, or complex type N-glycans
   Shih-Chang Lin, National Tsing Hua University

82. Translatome of CHO cells: Towards bridging the gap between transcriptome and proteome
   Dong-Yup Lee, National University of Singapore

83. Large-scale screening identifies a novel microRNA, miR-15a-3p, which induces apoptosis in human cancer cell lines
   Joseph Shiloach, NIH

84. Profiling deacetylase activities in cell lysates with peptide arrays and SAMDI mass spectrometry application to CHRF cell megakaryocytic differentiation
   William M. Miller, Northwestern University

85. Controlling host-cell based proteolytic activity in CHO cultures
   Kunal Aggarwal, Novartis Vaccines and Diagnostics

86. Scale-down tools for evaluation of perfusion cultivations
   Martin Heitmann, Novo Nordisk

87. Challenges and solutions of continuous, scalable cultivation for anchorage dependent cells in single-use bioreactors
   Brian Lee, PBS Biotech, Inc.

88. Approaches to screening and characterization of cloned CHO cell lines containing sequence variants
   Karin Anderson, Pfizer

89. An unexpected design solution to mAb aggregation
   Alice Furgeson, Pfizer
90. Development of large-scale fed-batch process for production of recombinant influenza vaccine
   Jamal Meghrous, Protein Sciences

91. Case studies for utilization of conventional and CFD approaches for successful scale up and scale down of bioreactor processes for monoclonal antibodies
   Michelle LaFond, Regeneron Pharmaceuticals

92. Parallelized construct screening and scale-up of full-length membrane protein expression for biophysical studies
   Georg Schmid, Roche Diagnostics GmbH

93. Improved understanding and control of low fucose content of mAbs expressed in glycoengineered CHO cell lines
   Christine Jung, Roche Diagnostics GmbH

94. Spectroscopic tools for an automated suspension cell culture screening system
   Sven Markert, Roche Diagnostics GmbH

95. Characterization of the influence of cultivation parameters on extracellular modifications of antibodies during fermentation
   Christian Hakemeyer, Roche Diagnostics GmbH

96. Improving product safety profiles: Host cell lines deficient in CMP-N-acetylneuraminic acid hydroxylase (CMAH) and alpha-1-3-galactosyltransferase (GGTA1)
   Joaquina Mascarenhas, SAFC

97. Serum-free suspension culturing of human cells: Adaptation and cryopreservation
   Kamilla Swiech, School of Pharmaceutical Sciences of Ribeirao Preto

98. Comparison of PiggyBac mediated cell pool generation with different CHO host systems
   Sowmya Balasubramanian, SV-IBI-LBTC/EPFL

99. Evaluation and characterization of the ambr250 system for use with stable cell and transient protein production
   Melisa Carpio, Takeda California

100. Development of a chemically defined platform media for MAb production
    Shinobu Kuwae, Takeda Pharmaceutical Company

101. Towards a single chemically defined medium for combining transfection and cultivation of HEK and CHO cell lines
    Tim Beckmann, Xell AG

102. Single cell omics
    Jeff Chalmers, The Ohio State University

103. Metabolite profiling of a host CHO-S cell line adapted to different culture media: An experimental platform to dissect metabolite requirements to fuel cell growth, viability and potential productivity
    Mark Elvin, The University of Manchester

104. Molecular markers of CHO cells phenotype changes during prolonged culture
    Imelda Juniarsih, The University of Manchester
105. Transcriptomics-guided design of synthetic regulatory elements
Joseph K. Cheng, The University of Texas at Austin

106. Generation of high-producing cell lines by cell cycle checkpoint engineering in CHO cells
Rima Matsuyama, The University of Tokushima

107. Analysis of anti-aggregation effect in trehalose-supplemented CHO cell culture
Takeshi Omasa, The University of Tokushima

108. Optimization of HIV-1 virus-like particles production in CAP-T cell system
Francesc Godia, Universitat Autonoma de Barcelona

109. High-level recombinant protein production in CHO cells using the cumate gene-switch
Adeline Poulain, Universite de Montreal

110. A serum-free adapted CV-1 cell line as a potential host cell line for an oncolytic vaccinia virus production
Shunchang Liu, University College London

111. Cell therapy bioprocess economics and optimization
Suzanne Farid, University College London

112. High throughput cell culture to evaluate the relationship between antibody titre and host cell protein levels
Alma Mona Antemie, University College London

113. Varied CHO cell responses to amino acid limitations
Navid Ghaffari, University of British Columbia

114. Using systems approaches to assess impacts of genomic variation in chinese hamster ovary cell lines
Nathan Lewis, University of California, San Diego

115. A genome-scale model of Chinese hamster ovary cell metabolism for multiomic data analysis and optimal bioprocess design
Hooman Hefzi, University of California, San Diego

116. Global study of metabolic shift using an extended genome scale model for mammalian cells
Ziomara P. Gerdtzen, University of Chile

117. Microparticles: a new therapeutic and experimental modality? The case of megakaryocytic microparticles
Eleftherios Terry Papoutsakis, University of Delaware

118. Effect of media supplements on the glycosylation profile in MAbs
Devesh Radhakrishnan, University of Delaware

119. Evaluation of Chinese hamster ovary host cell protein expression over varied cultivation duration
Kristin N. Valente, University of Delaware

120. Generating a novel cell line suitable for effective production of biopharmaceuticals using high-energy irradiation
Satoshi Terada, University of Fukui
121. **Culture supplement obtained from natural products for improving productivity in serum-free culture of mammalian cells**  
Akiko Ogawa, Suzuka National College of Technology

122. **Characterisation of the secretory bottleneck in recombinant erythropoietin (EPO) production in Chinese hamster ovary (CHO) cells.**  
Rodrigo Maldonado-Agurto, University of Manchester

123. **Use of site-direct integration to study genomic and transcriptional stability of different promoters**  
Mario Pereira, University of Manchester

124. **The variable glycosylation profiles generated for IGG1 and chimeric camelid antibodies and their modifications through lowered culture redox potential**  
Ben Dionne, University of Manitoba

125. **Effect of N-glycosylation on the structure and function of a heavy chain monoclonal antibody**  
Natalie J. Krahn, University of Manitoba

126. **The synthesis and enrichment efficiency of carboxymethyl chitosan for 'pull down' glycoproteomics**  
Edward Bodnar, University of Manitoba

127. **In vitro modification of monoclonal antibody glycans using glycosylation inhibitors: Effects on production, activity and stability**  
Maureen Spearman, University of Manitoba

128. **The role of glucose and glutamine regulated metabolic pathways on glycosylation of a heavy chain monoclonal antibody in CHO cells**  
Venkata Tayi, University of Manitoba

129. **A scalable in vitro system for the generation of large quantities of stem cell derived hepatocytes**  
Ravali T. Raju, University of Minnesota

130. **Genetic contrasts at the genomic level in CHO cell lines**  
Kyoung Ho Lee, University of Minnesota

131. **Comparative transcriptome dynamics in CHO cell lines**  
Liang Zhao, University of Minnesota

132. **A systems biology approach to improve host cells for biopharmaceutical production**  
Camila Orellana, University of Queensland

133. **Improving culture performance and antibody production in CHO cell culture processes by reducing the Warburg effect**  
Maria Buchsteiner, University of Queensland

134. **Engineering the expression of "difficult-to-express" recombinant monoclonal antibodies in Chinese hamster ovary cells**  
Leon Phillip Pybus, University of Sheffield

135. **Synthetic promoters for CHO cell engineering**  
Adam Brown, University of Sheffield
| 136. | **Hyperosmolality and its effects on antibody producing CHO cells**  
Jennifer Pfizenmaier, University of Stuttgart |
| 137. | **Comparing furin expression and proprotein convertases activity in CHO and HEK cells**  
Aileen Zhou, University of Toronto |
| 138. | **A process analytical technology (PAT) strategy to improve manufacturing excellence of a perfusion per.C6® cultivation process**  
Sarah Mercier, University of Wageningen |
| 139. | **Differential iTRAQ proteomics to identify protein networks pertinent to mAb production in CHO cell lines**  
Owen Z. Woody, University of Waterloo |
| 140. | **Characterization of alternative promoters to stagger protein expression using the baculovirus-insects cell system**  
Steve George, University of Waterloo |
| 141. | **Supplementing glycosylation, metabolomics of enhanced feeding strategies**  
Eric J.M. Blondeel, University of Waterloo |
| 142. | **13C flux analysis of metabolic phenotypes associated with peak productivity and apoptotic resistance in CHO cells**  
Jamey D. Young, Vanderbilt University |
| 143. | **Impact of a signal peptide on mAb product quality**  
Jill Cai, Wuxi AppTec Co., Ltd. |
| 144. | **Product quality optimization (including ADCC activity) of bio-therapeutics via cell culture optimization**  
Jincai Li, Wuxi AppTec Co., Ltd. |
| 145. | **Advantages and challenges of developing bispecific antibody biotherapeutics**  
David Zhao, YZY Biopharma |
| 146. | **Integrative -OMICS data approachon the road to understand MIRNA-engineered CHO cell phenotypes**  
Vaibhav Jadhav, BOKU University |
| 147. | **Development and characterization of an orbitally shaken disposable 12 L bioreactor suitable for mammalian and microcarrier cultures**  
Tim Burgin, Kuhner Shaker |
| 148. | **Characterization of a novel protein antiviral from Lononmia obliqua using bioinformatics tools and activity analysis by real time**  
Ana Carmo, Butantan Institute |
| 149. | **Characterization of biological variance in time-series metabolomic data of cultured mammalian cells**  
Huong Le, Amgen |
| 150. | **Robust high yielding platform for biopharmaceutical protein production**  
Kiyoshi Hirakawa, Ajinomoto |
| 151. | **Development of a xeno-free environment for human keratinocyte culture**  
Imad Debbah, Universite de Laval |
152. Development of a scalable, high performance bio-production process using scale down culture systems
   Kirti Chaturvedi, BDAB

153. Monoclonal antibody producing CHO cells fed-batch-batch cultures assisted by an in silico metabolomic platform
   Julien Robitaille, Ecole polytechnique de Montreal

154. Ambr48 as a tool for process development and key process parameter identification for the manufacture of a biosimilar in CHO cells
   Matthew Zustiak, Gallus Biopharmaceuticals

155. Production of VSV-G VLPs by transient transfection of HEK 293 suspension cell culture and application in nucleic acid delivery
   Igor Slivac, Universite de Laval and PROTEO and THECELL

156. Using gabor wavelet features and multivariate image analysis techniques to assess the impact of culture medium on myoblast morphology observed under phase contrast microscopy
   Pierre-Marc Juneau, Laval University

157. Genome editing with novel CRSPR-Cas system for reduced lactate production in CHO cells
   Camila A. Wilkens, University of Chile

158. Metabolic engineering of protein production using an in silico platform
   Edwige Arnold, Ecole Polytechnique de Montreal

159. PEI-based transient gene expression in CHO cells using the cumate gene-switch
   Mathias Mangion, Universite de Laval and PROTEO and THECELL

160. Use of an alternating tangential flow system (ATF) for the production of fusion proteins in high density CHO cells cultures
   Cristian Paillet, Zelltek S.A.

161. Effect of process modifications on glycation and drug substance color
   Natarajan Vijayasankaran, Genentech, Inc.

162. Impact of raw material variability on commercial CHO cell culture manufacturing
   Jun Luo, Genentech, Inc.

163. UNICAN: Dual capability in single use bioreactors
   Ekta Mahajan, Genentech, Inc.

164. Product quality lessons learned from developing and implementing a chemically-defined CHO platform cell culture process
   Martin Gawiltzek, Genentech, Inc.

165. Poor recovery from thaw troubleshooting
   Meg Tung, Genentech, Inc.

166. Evolving pilot plant flexibility & capacity - Key lessons learned during the implementation of single-use bioreactors
   Arthi Narayanan, Genentech, Inc.
167. Evaluating and minimizing sequence variants during recombinant protein production
   Michael W. Laird, Genentech, Inc.

168. Product quality control during late stage cell culture process development
   Ana Veronica Carvalhal, Genentech, Inc.

169. In situ Raman spectroscopy for bioreactor characterization by simultaneous real-time
    monitoring of multiple process parameters
   Lada Laenen, Genzyme, A Sanofi Company

170. Achieving long-term, high-density cell cultures with alternating tangential flow (ATF) cell
    separation technology
   Jason Walther, Genzyme, A Sanofi Company

171. Strategies to sustain long term high cell density culture for the production of monoclonal
    antibodies
   Marcella Yu, Genzyme, A Sanofi Company

172. The effect of selected amino acid supplements on monoclonal antibody production by
    using CHO cell in scale-down bioreactors
   Wei-Kuang Chi, Development center for biotechnology

173. Insights into the metabolism of CHO cells under key nutrient limitations
   Nuno Carinhas, IBET/ITQB-UNL

174. Elucidating the impact of copper limitation on energy metabolism in Chinese hamster
    ovary cells using 13C-metabolic flux analysis
   Chetan Goudar, Amgen Inc.

175. Localization and non-apoptotic action of Bcl-xL in chinese hamster ovary cells
   Abasha Lewis, IRP NIH-NIDA

176. Effects of low glucose and glutamine concentrations on the glycosylation of CHO EG2-
    hFc monoclonal antibody
   Carina Villacres Barragan, University of Manitoba

177. Implementing adventitious agent barriers for small-volume media preparations for a
    commercial cell culture process
   Fikret Kulenovic, Genentech

178. Troubleshooting of a commercial cell culture production process
   Jason Goodrick, Genentech

179. Exploiting the dielectric properties of CHO cells to monitor apoptotic events in a
    bioprocess
   Katrin Braasch, University of Manitoba

180. Reliable mAb production in CHO – quite a challenge in the light of raw material lot to lot
    variations
   Marco Jenzsch, Roche Pharma Biotech

181. Trouble-shooting scale-up challenges for a pH-sensitive cell line during process
    development and clinical manufacturing
   Melissa S. Mun, Genentech, Inc.

182. Scale free manufacturing model using perfusion
   Olivier Berteau, APICells Inc.
183. Use of multivariate prediction to determine optimal endpoint of a bioreactor process  
   Patrick O. Gammell, Amgen

184. Viral barriers for upstream cell culture processes: UV-C media treatment combined with gamma irradiated Donor Bovine Serum  
   Sofie Goetschalckx, Genzyme

185. Impact of LC:HC ratio of stable IgG expression and quality  
   Steven Ho, BTI

186. Digital multiplexed mRNA analysis of N-glycosylation-related genes in recombinant Chinese hamster ovary cells treated with sodium butyrate  
   Eun Gyo Lee, KIIBB

187. Culture supplement obtained from natural products for improving productivity in serum-free culture of mammalian cells  
   Akiko Ogawa, Suzuka National College of Technology

188. Development of a dual cassette viral reporter vector to model endothelial progenitor cell adhesion and differentiation using live cell imaging  
   Marieve Boulanger, Universite Laval

189. Evaluation of siRNA technology as a tool for transient cell line engineering  
   Neha Dhami, UCB/University of Manchester

190. Investigation of tricarboxilic acid cycle intermediates to control ammonia generation and to enhance cell culture performance  
   Oscar Lara-Velasco, GlaxoSmithKline

191. Extended growth and enhanced productivity in CHO-K1 and CHO DG44 cultures upon application of a chemically defined feeding strategy  
   Karen A. Benedict, Kerry – waiting for new corp cc to register

192. Feasibility of therapeutically using a beta-peptide hydrogel to treat spinal cord injury  
   Stephan Lindsey, A.I. duPont Hospital for Children/Nemours - waiting for funding, need more time to reg

193. Intracellular metabolic flux balance analysis of CHO cells supplemented with wheat hydrolysates for improved mAb production and cell-growth  
   Seongkyu Yoon, University of Massachusetts Lowell

194. Development and optimization of agitation in microcarrier-based cell therapy cultures in stirred-tank bioreactors  
   Biren Mistry, Celgene Cellular Therapeutics

195. Rapid Development and Scale-up of a Biosimilar  
   Claudia Berdugo, CookPharmica LLC

196. Effects of increased osmolarity on growth, productivity, intracellular osmolytes, and gene expression in industrial fed-batch CHO cell cultures  
   Matthew DeSieno, SUNY College of Nanoscale Science and Engineering

---

Requested more time to register
Have not respond